PDCD1 and neoplasm: Treatment strategies represented by ICIs activate the body’s anti-tumor immune response by targeting key pathways such as PD-1(Programmed Cell Death Protein 1), PD-L1, and CTLA-4(Cytotoxic T-Lymphocyte Associated Protein 4) (3, 4).